Amgen reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and potential Ozempic competitor MariTide, however, Wall Street wasn’t very impressed.

Prime Minister Justin Trudeau of Canada is the first foreign G7 leader to visit President-elect Donald J. Trump since the election. He is under pressure to persuade Mr. Trump to back down from his ...

Police in Moscow raided multiple bars early Saturday and arrested the director of a gay travel agency under laws criminalising "LGBT propaganda", state media reported. Russian security forces ...

Novo Nordisk (NVO) is out of investors' favor in the second half of the year, and so are its peers in the obesity market. For Novo Nordisk, this period was marked by the lack of upside revisions ...

Nov. 12, 2024 — New research has found that people with a genetic defect in their ability to digest sucrose eat less cake, sweets and chocolate, which could hold the key to helping the wider ...

Weight loss benefits from Amgen's monthly injection MariTide miss investor expectations MariTide's trial results comparable to Novo Nordisk and Eli Lilly drugs, with slightly more side effects ...

The Biden administration proposed on Tuesday a new rule that could significantly expand coverage of anti-obesity medications for Americans under Medicare and Medicaid. Currently, these government ...

(Bloomberg) -- Amgen Inc. shares fell the most in 23 years after its experimental obesity shot failed to significantly outperform rivals and showed a high rate of gastrointestinal side effects.

In a report released today, James Shin from Deutsche Bank maintained a Hold rating on Amgen (AMGN – Research Report), with a price target of $305.00. Don't Miss our Black Friday Offers: Unlock ...

Novo Nordisk’s median P/E ratio has been 26.40 from 2010 to the present. The following price predictions are based on a 25 P/E. In the subsequent 5 years to follow, Novo Nordisk’s newest ...

Deutsche Bank says Amgen’s (AMGN) MariTide’s Phase 2 press release “underwhelms” with 20% weight loss from Cohort A and 17% weight loss from Cohort B at 52-weeks, with it being unclear if ...